Krystal Biotech, Inc. (NASDAQ: KRYS) is a Healthcare company (Biotechnology) with a market capitalization of $8.8B. The Maz Rating grades it against the other companies in its sector.
Krystal Biotech, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $298.55, Krystal Biotech, Inc. trades at 38.8x trailing earnings, 18.8x sales and 6.1x book value, with an EV/EBITDA of 33.2. Over the last twelve months it generated about $472M of revenue and $228M of net income. It runs a gross margin of 93.4%, an operating margin of 48.4% and a net margin of 47.9%. It shows return on equity of 17.0%, return on invested capital of 13.7% and a free cash flow yield of 3.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 7.89. Over the past 52 weeks the share price ranged from $202.99 to $382.54, with a beta of 0.50.
Krystal Biotech, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 18 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Krystal Biotech, Inc. (KRYS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.2% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 9.32% / 33% · Receivables / Mkt Cap (36m) 1.36% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 9.32% / 33.33% · Receivables / Mkt Cap (24m) 1.36% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 58.6% / 33.33% · Receivables / Avg Assets (4Q) 9.05% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 57.5% / 33.33% · (Cash+Recv) / Total Assets 65.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Krystal Biotech, Inc. (KRYS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Krystal Biotech, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Krystal Biotech, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.